Verrica Pharmaceuticals Inc. has announced its financial results for the third quarter of 2026, demonstrating significant growth in revenue and operational advancements. The company reported record U.S. YCANTH net product revenue of $5.7 million, up 11.9% from the previous quarter and 57.9% year-over-year. This increase reflects Verrica's continued success in the dermatological therapeutics market, particularly in treating molluscum contagiosum.
Jayson Rieger, President and Chief Executive Officer of Verrica, stated, "Verrica made progress in growing our commercial YCANTH business while advancing our late-stage pipeline for two of the most prevalent skin diseases. We are now turning our focus to maximize conversion of written to filled prescriptions and ensuring optimal insurance coverage." The company is also executing on its label expansion strategy for YCANTH into common warts, with topline data from pivotal trials expected in early 2027.
Verrica Pharmaceuticals Inc. operates within the pharmaceutical preparations industry, focusing on developing and commercializing medications for dermatological diseases. The company is publicly traded on the Nasdaq under the ticker symbol VRCA. Recent filings include a Schedule 13G/A and a 10-Q, both filed on November 13, 2026, indicating ongoing regulatory compliance and transparency.
In its recent filing, Verrica highlighted its achievements in the third quarter, including the completion of enrollment in the first pivotal trial for common warts and significant revenue growth. The company also achieved predefined revenue and operational milestones under its credit facility, unlocking access to $27.5 million in growth capital.
This financial update is expected to impact various stakeholders, including investors, healthcare providers, and patients. The positive results may enhance investor confidence and attract new investments, while healthcare providers may benefit from the expanded treatment options for common warts and other dermatological conditions.
Looking ahead, Verrica plans to continue its clinical trials and explore the development of its oncolytic peptide, VP-315, for treating Gorlin syndrome, a rare genetic disease. The company is well-positioned to leverage its recent successes to further enhance its market presence and drive future growth.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










